Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the moment, Eli Lilly.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The Food and Drug Administration declared an end to the scarcity of Eli Lilly’s highly in-demand weight-loss and diabetes drugs on Thursday.
In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.
Novo Nordisk’s share price fell over 8% on Wednesday after the company reported lower-than-expected sales of Wegovy.
feat. Disney’s Fitbit for kids, Chat bots that mirror their users & AR Commerce3 new patent summaries this week from Disney, Microsoft and PayPal
Three new patents from Facebook, Twitter and Microsoft, including live-streaming with video reactions, multiple message quotes & more.
3 patents from Apple, Intel and Amazon, feat. Spatial Audio Navigation, VR Keyboards & Biometric Doorbells.